- User Profile
- Watchlists
- Gesundheitswesen & Finanzdienstleistungen
Gesundheitswesen & Finanzdienstleistungen
Watching
50
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
PYPL PayPal Holdings US$56.82n/aintrinsic discount 19.2%7D 11.7%3M The author hasn't set a fair value for PYPL | ||||||
ABT Abbott Laboratories US$101.66n/aintrinsic discount 10.4%7D 9.6%3M The author hasn't set a fair value for ABT | ||||||
XRAY DENTSPLY SIRONA US$13.46n/aintrinsic discount 5.3%7D 9.3%3M The author hasn't set a fair value for XRAY | ||||||
CRCL Circle Internet Group US$65.45n/aintrinsic discount 3.9%7D -31.8%3M The author hasn't set a fair value for CRCL | ||||||
COIN Coinbase Global US$160.43n/aintrinsic discount 1.9%7D -18.1%3M The author hasn't set a fair value for COIN | ||||||
BAC Bank of America US$60.42n/aintrinsic discount 1.5%7D 13.0%3M The author hasn't set a fair value for BAC | ||||||
BMY Bristol-Myers Squibb US$60.16n/aintrinsic discount 1.4%7D 1.3%3M The author hasn't set a fair value for BMY | ||||||
GILD Gilead Sciences US$133.21n/aintrinsic discount 1.4%7D -0.06%3M The author hasn't set a fair value for GILD | ||||||
JPM JPMorgan Chase US$338.87n/aintrinsic discount 1.3%7D 8.3%3M The author hasn't set a fair value for JPM | ||||||
HSBC HSBC Holdings US$99.01n/aintrinsic discount 0.9%7D 9.2%3M The author hasn't set a fair value for HSBC | ||||||
GS Goldman Sachs Group US$1,055.03n/aintrinsic discount 0.9%7D 13.9%3M The author hasn't set a fair value for GS | ||||||
TMO Thermo Fisher Scientific US$526.23n/aintrinsic discount -0.4%7D 0.3%3M The author hasn't set a fair value for TMO | ||||||
AXP American Express US$351.93n/aintrinsic discount -0.7%7D 6.7%3M The author hasn't set a fair value for AXP | ||||||
BRK.B Berkshire Hathaway US$491.25n/aintrinsic discount -1.1%7D 4.9%3M The author hasn't set a fair value for BRK.B | ||||||
UNH UnitedHealth Group US$421.55n/aintrinsic discount -1.8%7D 21.8%3M The author hasn't set a fair value for UNH | ||||||
IBKR Interactive Brokers Group US$91.68n/aintrinsic discount -2.0%7D 15.1%3M The author hasn't set a fair value for IBKR | ||||||
LLY Eli Lilly US$1,146.90n/aintrinsic discount -3.0%7D 27.0%3M The author hasn't set a fair value for LLY | ||||||
JNJ Johnson & Johnson US$248.82n/aintrinsic discount -3.5%7D 10.0%3M The author hasn't set a fair value for JNJ | ||||||
ETOR eToro Group US$36.68n/aintrinsic discount -4.0%7D -1.8%3M The author hasn't set a fair value for ETOR | ||||||
MS Morgan Stanley US$210.94n/aintrinsic discount -4.6%7D 11.4%3M The author hasn't set a fair value for MS | ||||||
HIMS Hims & Hers Health US$32.70n/aintrinsic discount -4.9%7D 9.9%3M The author hasn't set a fair value for HIMS | ||||||
CRSP CRISPR Therapeutics US$46.99n/aintrinsic discount -7.2%7D -15.4%3M The author hasn't set a fair value for CRSP | ||||||
EW Edwards Lifesciences US$85.00n/aintrinsic discount -7.4%7D 6.6%3M The author hasn't set a fair value for EW | ||||||
HOOD Robinhood Markets US$99.28n/aintrinsic discount -9.6%7D 14.9%3M The author hasn't set a fair value for HOOD | ||||||
ISRG Intuitive Surgical US$353.17n/aintrinsic discount -13.3%7D -21.7%3M The author hasn't set a fair value for ISRG |
Watching
50
| Company | Price & Valuation | FV & Narrative | Valuation | Growth | Analyst Target | |
|---|---|---|---|---|---|---|
PYPL PayPal Holdings 19.2%7D 11.7%3M | US$56.82 n/aintrinsic discount | The author hasn't set a fair value for PYPL | PE 9.9x | E -1.6% | US$52.42 | |
ABT Abbott Laboratories 10.4%7D 9.6%3M | US$101.66 n/aintrinsic discount | The author hasn't set a fair value for ABT | PE 32.8x | E 16.8% | US$118.54 | |
MSTR Strategy 6.2%7D -40.3%3M | US$97.82 n/aintrinsic discount | The author hasn't set a fair value for MSTR | PB 1x | E 88.5% | US$303.64 | |
XRAY DENTSPLY SIRONA 5.3%7D 9.3%3M | US$13.46 n/aintrinsic discount | The author hasn't set a fair value for XRAY | PS 0.7x | E 76.9% | US$13.38 | |
CRCL Circle Internet Group 3.9%7D -31.8%3M | US$65.45 n/aintrinsic discount | The author hasn't set a fair value for CRCL | PS 5.7x | E 47.7% | US$121.44 | |
MTB M&T Bank 2.8%7D 14.0%3M | US$249.44 n/aintrinsic discount | The author hasn't set a fair value for MTB | PE 12.6x | E 1.8% | US$252.47 | |
SPGI S&P Global 2.4%7D 0.8%3M | US$448.35 n/aintrinsic discount | The author hasn't set a fair value for SPGI | PE 27.8x | E 7.4% | US$518.72 | |
BNTX BioNTech 2.3%7D -17.4%3M | US$92.16 n/aintrinsic discount | The author hasn't set a fair value for BNTX | PS 7.3x | E 3.7% | US$121.56 | |
BLK BlackRock 2.2%7D 1.1%3M | US$1,054.11 n/aintrinsic discount | The author hasn't set a fair value for BLK | PE 24.8x | E 10.8% | US$1,313.50 | |
ABBV AbbVie 2.2%7D 23.5%3M | US$253.38 n/aintrinsic discount | The author hasn't set a fair value for ABBV | PE 124.5x | E 27.3% | US$266.57 | |
COIN Coinbase Global 1.9%7D -18.1%3M | US$160.43 n/aintrinsic discount | The author hasn't set a fair value for COIN | PE 52.8x | E 30.8% | US$222.04 | |
MA Mastercard 1.8%7D 7.1%3M | US$547.44 n/aintrinsic discount | The author hasn't set a fair value for MA | PE 31.1x | E 11.1% | US$643.84 | |
BAC Bank of America 1.5%7D 13.0%3M | US$60.42 n/aintrinsic discount | The author hasn't set a fair value for BAC | PE 13.2x | E 5.4% | US$68.11 | |
BMY Bristol-Myers Squibb 1.4%7D 1.3%3M | US$60.16 n/aintrinsic discount | The author hasn't set a fair value for BMY | PE 16.9x | E -2.4% | US$62.96 | |
GILD Gilead Sciences 1.4%7D -0.06%3M | US$133.21 n/aintrinsic discount | The author hasn't set a fair value for GILD | PE 17.9x | E 20.2% | US$157.59 | |
JPM JPMorgan Chase 1.3%7D 8.3%3M | US$338.87 n/aintrinsic discount | The author hasn't set a fair value for JPM | PE 14.2x | E 1.3% | US$367.95 | |
BX Blackstone 1.3%7D -3.8%3M | US$123.61 n/aintrinsic discount | The author hasn't set a fair value for BX | PE 31.8x | E 27.4% | US$138.95 | |
USB U.S. Bancorp 1.3%7D 11.1%3M | US$63.14 n/aintrinsic discount | The author hasn't set a fair value for USB | PE 12.6x | E 6.2% | US$69.98 | |
PFE Pfizer 1.1%7D -9.4%3M | US$24.75 n/aintrinsic discount | The author hasn't set a fair value for PFE | PE 18.9x | E -1.7% | US$28.75 | |
ZTS Zoetis 1.1%7D -35.5%3M | US$76.20 n/aintrinsic discount | The author hasn't set a fair value for ZTS | PE 12x | E 5.2% | US$114.76 | |
AMGN Amgen 1.0%7D 5.6%3M | US$364.17 n/aintrinsic discount | The author hasn't set a fair value for AMGN | PE 25.2x | E 7.6% | US$356.69 | |
FISV Fiserv 1.0%7D -18.3%3M | US$51.68 n/aintrinsic discount | The author hasn't set a fair value for FISV | PE 8.6x | E 5.3% | US$67.37 | |
HSBC HSBC Holdings 0.9%7D 9.2%3M | US$99.01 n/aintrinsic discount | The author hasn't set a fair value for HSBC | PE 16.2x | E 11.3% | US$96.46 | |
GS Goldman Sachs Group 0.9%7D 13.9%3M | US$1,055.03 n/aintrinsic discount | The author hasn't set a fair value for GS | PE 16.2x | E 2.6% | US$1,126.35 | |
V Visa 0.8%7D 16.3%3M | US$360.57 n/aintrinsic discount | The author hasn't set a fair value for V | PE 30.8x | E 11.1% | US$401.47 | |
NVO Novo Nordisk 0.7%7D 25.8%3M | US$49.61 n/aintrinsic discount | The author hasn't set a fair value for NVO | PE 11.9x | E -1.1% | US$47.98 | |
DHR Danaher 0.5%7D 3.4%3M | US$201.11 n/aintrinsic discount | The author hasn't set a fair value for DHR | PE 38.7x | E 17.3% | US$242.52 | |
MRK Merck 0.3%7D 10.5%3M | US$124.40 n/aintrinsic discount | The author hasn't set a fair value for MRK | PE 34.4x | E 21.0% | US$134.04 | |
KKR KKR 0.06%7D -7.2%3M | US$96.97 n/aintrinsic discount | The author hasn't set a fair value for KKR | PE 31.1x | E 26.7% | US$124.08 | |
RMD ResMed 0.06%7D -10.2%3M | US$198.61 n/aintrinsic discount | The author hasn't set a fair value for RMD | PE 18.9x | E 6.6% | US$248.73 | |
MDT Medtronic -0.3%7D 1.6%3M | US$83.29 n/aintrinsic discount | The author hasn't set a fair value for MDT | PE 22.2x | E 10.1% | US$97.84 | |
TMO Thermo Fisher Scientific -0.4%7D 0.3%3M | US$526.23 n/aintrinsic discount | The author hasn't set a fair value for TMO | PE 28.6x | E 10.4% | US$591.27 | |
AXP American Express -0.7%7D 6.7%3M | US$351.93 n/aintrinsic discount | The author hasn't set a fair value for AXP | PE 21.7x | E 9.0% | US$374.94 | |
BRK.B Berkshire Hathaway -1.1%7D 4.9%3M | US$491.25 n/aintrinsic discount | The author hasn't set a fair value for BRK.B | PE 14.6x | E -2.4% | US$506.40 | |
WFC Wells Fargo -1.5%7D 5.9%3M | US$86.33 n/aintrinsic discount | The author hasn't set a fair value for WFC | PE 12.1x | E 3.4% | US$100.07 | |
UNH UnitedHealth Group -1.8%7D 21.8%3M | US$421.55 n/aintrinsic discount | The author hasn't set a fair value for UNH | PE 27.1x | E 14.4% | US$473.31 | |
IBKR Interactive Brokers Group -2.0%7D 15.1%3M | US$91.68 n/aintrinsic discount | The author hasn't set a fair value for IBKR | PE 39.3x | E 13.5% | US$99.99 | |
NVS Novartis -2.5%7D 1.1%3M | US$149.56 n/aintrinsic discount | The author hasn't set a fair value for NVS | PE 20.6x | E 9.3% | US$149.80 | |
LLY Eli Lilly -3.0%7D 27.0%3M | US$1,146.90 n/aintrinsic discount | The author hasn't set a fair value for LLY | PE 40.5x | E 16.4% | US$1,270.37 | |
JNJ Johnson & Johnson -3.5%7D 10.0%3M | US$248.82 n/aintrinsic discount | The author hasn't set a fair value for JNJ | PE 28.5x | E 9.2% | US$269.95 | |
SYK Stryker -3.7%7D -2.5%3M | US$319.14 n/aintrinsic discount | The author hasn't set a fair value for SYK | PE 36.7x | E 16.4% | US$386.52 | |
ETOR eToro Group -4.0%7D -1.8%3M | US$36.68 n/aintrinsic discount | The author hasn't set a fair value for ETOR | PE 12.2x | E 11.3% | US$56.93 | |
MS Morgan Stanley -4.6%7D 11.4%3M | US$210.94 n/aintrinsic discount | The author hasn't set a fair value for MS | PE 17x | E 2.2% | US$234.57 | |
HIMS Hims & Hers Health -4.9%7D 9.9%3M | US$32.70 n/aintrinsic discount | The author hasn't set a fair value for HIMS | PS 3.2x | E 71.7% | US$28.42 | |
CRMD CorMedix -6.5%7D 5.4%3M | US$7.78 n/aintrinsic discount | The author hasn't set a fair value for CRMD | PE 3.4x | E -4.5% | US$15.00 | |
CRSP CRISPR Therapeutics -7.2%7D -15.4%3M | US$46.99 n/aintrinsic discount | The author hasn't set a fair value for CRSP | PB 2.6x | E 64.8% | US$86.21 | |
EW Edwards Lifesciences -7.4%7D 6.6%3M | US$85.00 n/aintrinsic discount | The author hasn't set a fair value for EW | PE 45.5x | E 16.9% | US$99.00 | |
C Citigroup -8.5%7D -2.2%3M | US$128.72 n/aintrinsic discount | The author hasn't set a fair value for C | PE 13.1x | E 7.8% | US$154.00 | |
HOOD Robinhood Markets -9.6%7D 14.9%3M | US$99.28 n/aintrinsic discount | The author hasn't set a fair value for HOOD | PE 47.1x | E 15.5% | US$119.44 | |
ISRG Intuitive Surgical -13.3%7D -21.7%3M | US$353.17 n/aintrinsic discount | The author hasn't set a fair value for ISRG | PE 39.8x | E 12.1% | US$501.73 |